Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($) $ in Millions		3 Months Ended		6 Months Ended		21 Months Ended
		Jun. 29, 2025	Jun. 30, 2024	Jun. 29, 2025	Jun. 30, 2024	Jun. 29, 2025
Restructuring charges/(credits):
Employee terminations		$ (148)	$ 1,014	$ 236	$ 984
Asset impairments		44	41	217	66
Exit costs		30	49	94	63
Restructuring charges/(credits)	[1]	(74)	1,104	547	1,114
Transaction costs	[2]	0	0	0	5
Integration costs and other	[3]	56	150	113	237
Restructuring charges and certain acquisition-related costs		(18)	1,254	660	1,356
Additional depreciation––asset restructuring	[4]	4	4	7	8
Implementation costs	[5]	78	105	128	163
Total costs associated with acquisitions and cost-reduction/productivity initiatives		54	1,364	727	1,532
Biopharma [Member]
Restructuring charges/(credits):
Restructuring charges/(credits)		(406)	1,100	211	1,100
Biopharma [Member] | Manufacturing Optimization Program [Member]
Restructuring charges/(credits):
Restructuring charges/(credits)		(408)	1,300	(412)	1,300
Biopharma [Member] | Realigning Our Cost Base Program [Member]
Restructuring charges/(credits):
Restructuring charges/(credits)		(25)	(113)	562	(199)	$ 2,500
Other (income)/deductions––net [Member]
Restructuring charges/(credits):
Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net		(9)	2	(68)	5
Cost of sales [Member]
Restructuring charges/(credits):
Additional depreciation––asset restructuring	[4]	3	1	7	5
Implementation costs	[5]	26	49	46	65
Selling, informational and administrative expenses [Member]
Restructuring charges/(credits):
Additional depreciation––asset restructuring	[4]	0	3	0	3
Implementation costs	[5]	14	36	20	65
Research and development expense [Member]
Restructuring charges/(credits):
Implementation costs	[5]	$ 39	$ 20	$ 62	$ 33

[1] Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) credits of $406 million for the three months ended June 29, 2025 (including credits of $408 million for our Manufacturing Optimization Program and $25 million for our Realigning our Cost Base Program), (ii) charges of $211 million for the six months ended June 29, 2025 (including charges of $562 million for our Realigning our Cost Base Program and credits of $412 million for our Manufacturing Optimization Program) and (iii) charges of $1.1 billion for both the three and six months ended June 30, 2024 (including charges of $1.3 billion for our Manufacturing Optimization Program for both periods presented and credits of $113 million for the three months and $199 million for the six months ended June 30, 2024 for our Realigning our Cost Base Program). For all periods presented, Employee terminations include revisions of estimates of previously recorded accruals for severance benefits, driven in large part by higher-than-expected voluntary attrition.

[2] Represents external costs for banking, legal, accounting and other similar services.

[3] Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.

[4] Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.

[5] Represents incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.